PharmEasy Unlisted Share Price - Buy/Sell online
company-image

Unlisted Shares

PHYSICAL

Pharmeasy Essentials

As of may 27, 2024 PharmEasy share price is ₹10/ per unlisted share. The lot size of Pharmeasy share is 20000 shares. 52-week high for PharmEasy (API Holdings) stock price ₹23, while the 52-week low is ₹11.  The face value is ₹1/share. 

NOTE: Rates and lot size of PharmEasy unlisted shares mentioned above may be changes according to date and time. Kindly check the latest share price of PharmEasy with us.

ISIN

INE0DJ201029

Face Value

₹ 1

Total Share

6,14,20,41,070

Total Income

₹ 6,647.13 undefined

Profit After Tax

₹ ****

EPS

₹ ****

P/B

****

Market Capitalisation

₹ 6,080.62 Cr

Enterprise Value

₹ ****

Book Value

₹ 7.7

Intrinsic Value

₹ ****

Earnings Yield

-85.96 %

Sector

Health Care

Sub-sector

Pharmaceuticals

Category

Upcoming IPO

Cashflow - Operations

-₹ 744.17

Cashflow - Financing

853.49

Pharmeasy Growth

Compounded Sales Growth

1 Year

2 Year

3 Year

Return On Equity

2021

2022

2023

Highlights

image
  • E-Pharmacy Market Leader - API Holdings Limited, through its subsidiaries, develops and operates an integrated digital healthcare platform. The company offers teleconsultation; diagnostics and radiology tests; and Redbook, an enterprise resource planning (ERP) and pharmacy customer relationship management software. The company operates a consumer healthcare app called PharmEasy which enables on-demand, home delivery of pharmaceutical products to customers.
image
  • Revenue Growth - The company's revenue has experienced a substantial rise, climbing from ₹5,728 Cr in FY22 to ₹6,643 Cr in FY23, indicating a growth rate of 17.3%. Over the past three years, the company's revenue has consistently increased, achieving a compound annual growth rate (CAGR) of 118% from FY20 to FY23.
image
  • Profitability - The company's profitability has worsened over time. The EBIT margin, which was -44.3% in FY22, has improved to -25.1% in FY23, reflecting an improvement of 43.6%. The net profit margin of the company has further deteriorated from -70.7% in FY22 to 78.6% in FY23, demonstrating a decrease of 11.2% from FY22 to FY23.
image
  • Notable Investors - PharmEasy has attracted several prominent investors throughout its journey, with the current landscape looking a bit different from its peak valuation days. Some of the notable investors include TPG Group, Naspers Ventures, Kotak, Goldman Sachs, MacRitchie Investments, and Ivy Icon SolutionsManipal Group, the Indian healthcare conglomerate is set to become the single largest shareholder with a potential 18% stake, marking a significant development in PharmEasy's funding picture.
image
  • Investment Thesis - PharmEasy recently encountered a substantial 90% reduction in its valuation following a violation of crucial loan terms established by Goldman Sachs. To address this, PharmEasy intends to generate approximately ₹2,400 Cr through a rights issue, offering shares at a 90% discounted valuation. The rights issue is set at a valuation of around $800 million, with a per-share price of ₹5.
  • PharmEasy, previously valued at $5.6 billion with a share price of ₹130, has undergone a substantial correction, now standing at $800 million, marking an approximately 85% reduction. The positive shift in margins and the active involvement of the Manipal Group in the rights issue signify a potential turning point for the company. The Manipal Group's expertise in the healthcare sector adds a strategic vision to the company's trajectory.

Business Rating

image

Managment

lock starlock starlock starlock starlock star
image

Accounting Practice

lock starlock starlock starlock starlock star
image

Profatibility

lock starlock starlock starlock starlock star
image

Solvency

lock starlock starlock starlock starlock star
image

Growth

lock starlock starlock starlock starlock star
image

Valuation

lock starlock starlock starlock starlock star

Overall Ratings

lock starlock starlock starlock starlock star

Recommendation

lock starlock starlock starlock starlock star

Our Team

directorImage

Hardik Dedhia

( Co-Founder )

Hardik Dedhia is a Co-Founder of our Company. He joined Ascent Health and Wellness Solutions Private Limited, which merged into our Company pursuant to Merger 2020, as the Chief Technical Officer on April 1, 2016.

directorImage

Harsh Parekh

( Co-Founder and Whole-time Director )

​Harsh Parekh is a Co-founder and Whole-time Director of our Company. He holds a master’s degree in business administration from the School of Business Management, Narsee Monjee Institute of Management Studies, Mumbai.

Quantity

Invest

, Min. Investment: ₹